← Back to all trials
Completed
NCT07024862
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Conditions: Metastatic Non-small Cell Lung Cancer
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 103
Sponsor: Bristol-Myers Squibb
Location: Cardinal Health Dublin Ohio
Summary
The study will assess the long-term real-world outcomes among adults diagnosed with programmed death-ligand 1 (PD-L1) \
Eligibility Criteria
Inclusion Criteria:
* At least 18 years old at confirmed diagnosis with metastatic non-small cell lung cancer (NSCLC) (stage IV), squamous or non-squamous histology
* Initiated first-line (1L) combination nivolumab, ipilimumab, and 2 cycles of platinum-doublet chemotherapy (NIC) regimen between 01 January 2018 and 2 years prior to study launch
* Tumor programmed death-ligand 1 (PD-L1) negative expression (i.e., PD-L1 \
Source: ClinicalTrials.gov (NCT07024862). StuddyBuddy aggregates publicly available trial information.
